1,2,3,4,5,6-hexabromocyclohexane has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arlinghaus, RB; Chakraborty, SN; Hood, J; Kantarjian, H; Perrotti, D; Samanta, AK; Sun, X; Wang, Y | 1 |
1 other study(ies) available for 1,2,3,4,5,6-hexabromocyclohexane and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Topics: Animals; Apoptosis; Benzamides; Chromosomal Proteins, Non-Histone; Cyclohexanes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Chaperones; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Protein Phosphatase 2; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Pyrimidines; src-Family Kinases; Transcription Factors; Tyrphostins | 2009 |